Teleflex Incorporated (NYSE:TFX – Get Free Report) has earned an average recommendation of “Hold” from the twelve research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $152.90.
Several analysts have commented on TFX shares. Truist Financial boosted their price target on shares of Teleflex from $143.00 to $150.00 and gave the stock a “hold” rating in a research note on Monday, August 10th. Mizuho raised their price objective on Teleflex from $140.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research report on Wednesday, June 24th. Wall Street Zen raised Teleflex from a “sell” rating to a “hold” rating in a research note on Sunday, August 9th. Finally, Piper Sandler reissued an “overweight” rating and set a $169.00 price target (up from $160.00) on shares of Teleflex in a research note on Friday, August 7th.
Read Our Latest Analysis on Teleflex
Institutional Investors Weigh In On Teleflex
Teleflex Stock Down 0.1%
Shares of TFX stock opened at $130.85 on Friday. The company has a current ratio of 2.60, a quick ratio of 2.12 and a debt-to-equity ratio of 0.94. Teleflex has a 12 month low of $100.18 and a 12 month high of $145.00. The stock has a market cap of $5.54 billion, a P/E ratio of -5.62, a P/E/G ratio of 0.87 and a beta of 0.82. The company has a 50 day simple moving average of $135.72 and a two-hundred day simple moving average of $128.10.
Teleflex (NYSE:TFX – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical technology company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.28 by $0.48. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%.The business had revenue of $570.33 million for the quarter, compared to the consensus estimate of $559.59 million. During the same period in the previous year, the business earned $3.73 earnings per share. The business’s revenue was up 28.9% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. On average, research analysts expect that Teleflex will post 7.26 earnings per share for the current year.
Teleflex Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Friday, August 14th will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, August 14th. Teleflex’s dividend payout ratio is -5.84%.
Teleflex Company Profile
Teleflex Incorporated is a global medical technology company that develops, manufactures and supplies specialty medical devices for hospitals, clinicians and other health care providers. Its products are designed to support procedures in areas including vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgery and urology.
The company’s portfolio includes Arrow branded vascular access and catheter products, airway management devices, regional anesthesia products, surgical instruments, interventional devices and urological products.
Read More
- Five stocks we like better than Teleflex
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.
